FR194738 free base

Research use only, not for human use.

FR194738 inhibits squalene epoxidase activity in HepG2 cell homogenates with an IC50 of 9.8 nM.

FR194738 inhibits squalene epoxidase activity in HepG2 cell homogenates with an IC50 of 9.8 nM. FR194738 free base is a squalene epoxidase inhibitor.(In Vitro):FR194738 free base potently inhibits squalene epoxidase in HepG2 cell homogenate and liver microsomes in dogs and rats. FR194738 free base inhibits hamster liver microsomal squalene epoxidase activity in a concentration-dependent manner with an IC50 of 14 nM. In intact HepG2 cells, FR194738 free base inhibits the incorporation of [14C]acetate into free cholesterol and cholesteryl ester in a concentration-dependent manner(IC50s = 4.9 and 8.0 nM). FR194738 free base induces intracellular [14C]squalene accumulation and increases the incorporation of [14C]acetate into squalene.(In Vivo):FR194738 free base reduces the serum levels of total, non high density lipoprotein and high density lipoprotein cholesterol, and triglyceride. In hamsters, FR194738 free base(32 mg/kg) increases HMG-CoA reductase activity by 1.3-fold.

In intact HepG2 cells, FR194738 concentration-dependently inhibits the incorporation of [14C]acetate into free cholesterol and cholesteryl ester, with IC50s of 4.9 and 8.0 nM, respectively. FR194738 induces intracellular [14C]squalene accumulation. FR194738 increases the incorporation of [14C]acetate into squalene, an intermediate of cholesterol synthesis. FR194738 potently inhibits squalene epoxidase (SE) in HepG2 cell homogenate and liver microsomes in dogs and rats. The inhibitory effect of FR194738 in comparison to the HMG-CoA reductase inhibitors, Simvastatin, Fluvastatin and Pravastatin, on cholesterol biosynthesis in HepG2 cells is examined. Among these compounds, FR194738 is the most potent, with an IC50 of 2.1 nM. The IC50s of Simvastatin, Fluvastatin and Pravastatin are 40, 28 and 5100 nM, respectively. FR194738 inhibits hamster liver microsomal squalene epoxidase activity in a concentration-dependent manner with an IC50 of 14 nM.

Serum lipid levels in hamsters after daily administration of FR194738 and Pravastatin for 10 d are measured. FR194738 reduces the serum levels of total, non high density lipoprotein (HDL) and HDL cholesterol, and triglyceride. Treatment of hamsters with FR194738 increases HMG-CoA reductase activity by 1.3-fold at 32 mg/kg compared to the control group and does not significantly change that at 100 mg/kg.

——

GPCR/G Protein

Antibacterial

——

——

——

204067-45-8

439.66

C27H37NO2S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (227.45 mM)

CCN(C\C=C\C#CC(C)(C)C)Cc1cccc(OCC(C)(C)OCc2ccsc2)c1

——

(-20℃)

With Ice Pack

≥ 2 years